“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Novartis AG Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston May 31, 2017 Bay Area's ChemoCentryx Gets Up to $100M in New Capital Commitments January 3, 2018 Nestle Emerges as the Frontrunner for Merck KGaA's $5B Consumer Health Biz January 9, 2018
